Lv51
1460 积分 2023-10-18 加入
Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials
49分钟前
已完结
Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials
54分钟前
已完结
Nociceptor-derived CGRP enhances dermal type I conventional dendritic cell function to drive autoreactive CD8+ T cell responses in vitiligo
5天前
已完结
Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist
1个月前
已完结
Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States
1个月前
已完结
Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
1个月前
已完结
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause
1个月前
已关闭
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
1个月前
已完结
Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo
2个月前
已完结
Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies
2个月前
已完结
皖公网安备34019202002308
